Current Report Filing (8-k)
September 26 2022 - 5:01PM
Edgar (US Regulatory)
0001513525
false
0001513525
2022-09-26
2022-09-26
0001513525
us-gaap:CommonStockMember
2022-09-26
2022-09-26
0001513525
ADIL:WarrantsMember
2022-09-26
2022-09-26
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (date of earliest event reported): September 26, 2022
Adial
Pharmaceuticals, Inc.
(Exact
name of registrant as specified in charter)
Delaware
(State
or other jurisdiction of incorporation)
001-38323 |
|
82-3074668 |
(Commission File Number) |
|
(IRS Employer
Identification No.) |
1180
Seminole Trail, Suite 495
Charlottesville, Virginia 22901
(Address
of principal executive offices and zip code)
(434)
422-9800
(Registrant’s
telephone number including area code)
(Former
Name and Former Address)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any
of the following provisions:
☐ |
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting material pursuant
to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbols |
|
Name
of each exchange on which registered |
Common Stock |
|
ADIL |
|
NASDAQ |
Warrants |
|
ADILW |
|
NASDAQ |
Indicate
by check mark whether the registrant is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
7.01. Regulation FD Disclosure.
On
September 26, 2022, Adial Pharmaceuticals, Inc. (the “Company”) issued a press release announcing that Purnovate, Inc. (“Purnovate”),
a subsidiary of the Company, achieved positive in vivo data for PNV-5030 as a potential treatment for chronic pain.
The
information in this Item 7.01 and in the press release furnished as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed
to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the
liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended and shall not be incorporated by reference
into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless
of any general incorporation language in such filing.
The
press release furnished as Exhibit 99.1 to this Current Report on Form 8-K includes “safe harbor” language pursuant to the
Private Securities Litigation Reform Act of 1995, as amended, indicating that certain statements contained therein are “forward-looking”
rather than historical.
Item
8.01. Other Events.
On
September 26, 2022, the Company issued a press release announcing that Purnovate achieved positive in vivo data for PNV-5030 as a potential
treatment for chronic pain. The study was conducted in four groups of ten rats, which underwent surgical injury of the sciatic nerve.
After ten days of recovery, mechanical allodynia (measured in grams of pressure) was performed using a 50% withdrawal threshold, an accepted
animal model for measuring pain.
Certain
highlights of the study included the following:
● | PNV-5030
treatment was administered orally with a 15mg/kg dose. |
● | At
30 minutes post dose, PNV-5030 reduced pain by 43% compared to the control group, while acetaminophen
(APAP) doses did not have a significant effect (4.7g vs 2.7g, respectively, p<0.05). PNV-5030
also demonstrated a 49% improvement in pain reduction over acetaminophen (APAP-25mg/kg) (4.7g
vs 2.4g, respectively, p<0.05). |
● | At
60 minutes post dose, PNV-5030 reduced pain by 76% compared to the control group (5.3g vs
1.8g, respectively, p<0.05). PNV-5030 also demonstrated a 53% improvement in pain reduction
over acetaminophen (APAP-25mg/kg) (5.3g vs 2.4g, respectively, p<0.05). |
| |
● | At
120 minutes post dose, PNV-5030 reduced pain by 62% compared to the control group, while
acetaminophen (APAP) doses did not have a significant effect (4.7g vs 1.8g, respectively,
p<0.05). |
| |
● | At
180 minutes post dose, PNV-5030 reduced pain by 56% compared to the control group (3.4g vs
1.5g, respectively, p<0.05). PNV-5030 also demonstrated a 56% improvement in pain reduction
over acetaminophen (APAP-25mg/kg) (3.4g vs 1.5g, respectively, p<0.05). |
Item
9.01. Financial Statements and Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Dated: September 26, 2022 |
ADIAL PHARMACEUTICALS, INC. |
|
|
|
By: |
/s/
Cary J. Claiborne |
|
Name: |
Cary J. Claiborne |
|
Title: |
President and Chief Executive Officer |
2
Adial Pharmaceuticals (NASDAQ:ADIL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Adial Pharmaceuticals (NASDAQ:ADIL)
Historical Stock Chart
From Apr 2023 to Apr 2024